NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Published

Journal Article

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Full Text

Duke Authors

Cited Authors

  • Ettinger, DS; Wood, DE; Akerley, W; Bazhenova, LA; Borghaei, H; Camidge, DR; Cheney, RT; Chirieac, LR; D'Amico, TA; Dilling, T; Dobelbower, M; Govindan, R; Hennon, M; Horn, L; Jahan, TM; Komaki, R; Lackner, RP; Lanuti, M; Lilenbaum, R; Lin, J; Loo, BW; Martins, R; Otterson, GA; Patel, JD; Pisters, KM; Reckamp, K; Riely, GJ; Schild, SE; Shapiro, TA; Sharma, N; Swanson, SJ; Stevenson, J; Tauer, K; Yang, SC; Gregory, K; Hughes, M

Published Date

  • July 2016

Published In

Volume / Issue

  • 14 / 7

Start / End Page

  • 825 - 836

PubMed ID

  • 27407123

Pubmed Central ID

  • 27407123

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2016.0087

Language

  • eng

Conference Location

  • United States